FDA's 503B Comment Period on Tirzepatide and Semaglutide Has Closed: What Happens Next?

What Happened on 30 July 2026?

The public comment window on the FDA's proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List closed on 30 July 2026.[3] The docket had run since the Federal Register notice of 1 May 2026, with a single 30-day extension published 26 June 2026 that moved the original late-June deadline to the end of July.[2] Closing the window ends new public submissions to the record; it does not itself decide anything. As of this article's publication, the FDA has not announced a final determination, and no statutory deadline compels it to do so by a specific date.[4]

We covered the original proposal in detail in our 503B bulks list explainer published in mid-July; this article picks the story up at the next procedural milestone.

What Was the FDA's Original 30 April 2026 Proposal?

Section 503B of the Federal Food, Drug and Cosmetic Act lets FDA-registered outsourcing facilities compound drugs in bulk, ahead of any individual prescription, provided the bulk substance appears on the 503B Bulks List. On 30 April 2026, the FDA proposed not adding semaglutide, tirzepatide or liraglutide to that list, stating that after reviewing the nominations it "did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk drug substances."[1]

Outsourcing facilities had compounded large volumes of all three ingredients during the 2022–2024 supply shortages of the branded injectors — Ozempic and Wegovy, Mounjaro and Zepbound, and Saxenda and Victoza. Once FDA removed semaglutide and tirzepatide from its drug shortage list, that shortage-based legal basis lapsed, and outsourcing facilities nominated all three substances for permanent listing instead. The 30 April proposal was the FDA's answer: as written, it would close that permanent route.

What Happens Now That the Comment Window Is Shut?

The docket drew submissions from compounding-pharmacy trade groups, telehealth prescribers and patient advocates on one side, arguing that patient cost and access still justify a compounded alternative to the branded injectors, and from bodies favouring the exclusion on the other, echoing the FDA's own "clinical need has passed" reasoning.[3] With the window closed, the agency's next procedural step is to review that comment record and, in due course, publish a final rule or notice confirming, narrowing or reversing its April position.

If finalised as proposed, the exclusion would not touch compounding under the separate drug-shortage exception, which reopens automatically if a future shortage of any of the three branded products is declared — it would only close the permanent bulks-list route currently being sought.

How Does This Compare to the Separate 503A PCAC Vote?

It is easy to conflate this docket with the FDA's other major peptide-compounding proceeding of the summer, which reached its own milestone a week earlier.

Our PCAC vote outcome guide covers that separate hearing in full, and our Sandoz generic-tirzepatide ANDA guide covers a third, again distinct, tirzepatide filing under the standard Hatch-Waxman generic-drug pathway. None of the three proceedings overlaps with the others statutorily, even though all three touch the same handful of drug names.

What Should UK Researchers Take From This?

The 503B Bulks List, the outsourcing-facility framework and the "clinical need" standard applied throughout this docket are specific to the US prescription-drug supply chain. None of it changes the regulatory status of tirzepatide or semaglutide as research reagents under UK law, and none of it has bearing on the Human Medicines Regulations 2012 or MHRA guidance that governs research-reagent supply in Great Britain and Northern Ireland.

It is also a useful contrast with retatrutide, a compound this docket does not touch at all: retatrutide has no FDA-approved branded product, so it is not eligible for either the 503A or 503B compounding pathways discussed above — it remains available in the US only through Eli Lilly's own clinical-trial programme.

Velox Peptides does not stock semaglutide, tirzepatide or liraglutide; our metabolic-research range is built around retatrutide, supplied strictly as an HPLC-verified in vitro research reagent with a batch-specific certificate of analysis in our public CoA library — entirely separate from any branded product, US compounding-pharmacy pathway, or the docket described in this article.

Compounds referenced here are discussed for regulatory-news context only and are not all stocked by Velox Peptides. Where supplied, compounds are research reagents only, not medicines, and have not been evaluated by the MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions